How to select the frontline treatment for a patient with peripheral T-cell lymphoma

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Peripheral T-cell lymphomas are a diverse group of lymphoproliferative disorders with differing clinical presentations and biological behavior. The optimal treatment of these diseases is determined by an accurate diagnosis as well as determination of the unique phenotype, genetics and prognostic factors of each disease entity. While combination chemotherapy is the backbone of treatment for these patients, many patients may benefit from additional therapy such as brentuximab vedotin, radiation therapy, or stem cell transplantation.

Original languageEnglish (US)
Pages (from-to)783-788
Number of pages6
JournalLeukemia and Lymphoma
Volume57
Issue number4
DOIs
StatePublished - Apr 2 2016

Fingerprint

Peripheral T-Cell Lymphoma
Lymphoproliferative Disorders
Stem Cell Transplantation
Combination Drug Therapy
Radiotherapy
Therapeutics
Phenotype

Keywords

  • Frontline
  • NA
  • PTCL

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

How to select the frontline treatment for a patient with peripheral T-cell lymphoma. / Ansell, Stephen Maxted.

In: Leukemia and Lymphoma, Vol. 57, No. 4, 02.04.2016, p. 783-788.

Research output: Contribution to journalArticle

@article{2b70ab7977d34d24872848f887778534,
title = "How to select the frontline treatment for a patient with peripheral T-cell lymphoma",
abstract = "Peripheral T-cell lymphomas are a diverse group of lymphoproliferative disorders with differing clinical presentations and biological behavior. The optimal treatment of these diseases is determined by an accurate diagnosis as well as determination of the unique phenotype, genetics and prognostic factors of each disease entity. While combination chemotherapy is the backbone of treatment for these patients, many patients may benefit from additional therapy such as brentuximab vedotin, radiation therapy, or stem cell transplantation.",
keywords = "Frontline, NA, PTCL",
author = "Ansell, {Stephen Maxted}",
year = "2016",
month = "4",
day = "2",
doi = "10.3109/10428194.2016.1140760",
language = "English (US)",
volume = "57",
pages = "783--788",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - How to select the frontline treatment for a patient with peripheral T-cell lymphoma

AU - Ansell, Stephen Maxted

PY - 2016/4/2

Y1 - 2016/4/2

N2 - Peripheral T-cell lymphomas are a diverse group of lymphoproliferative disorders with differing clinical presentations and biological behavior. The optimal treatment of these diseases is determined by an accurate diagnosis as well as determination of the unique phenotype, genetics and prognostic factors of each disease entity. While combination chemotherapy is the backbone of treatment for these patients, many patients may benefit from additional therapy such as brentuximab vedotin, radiation therapy, or stem cell transplantation.

AB - Peripheral T-cell lymphomas are a diverse group of lymphoproliferative disorders with differing clinical presentations and biological behavior. The optimal treatment of these diseases is determined by an accurate diagnosis as well as determination of the unique phenotype, genetics and prognostic factors of each disease entity. While combination chemotherapy is the backbone of treatment for these patients, many patients may benefit from additional therapy such as brentuximab vedotin, radiation therapy, or stem cell transplantation.

KW - Frontline

KW - NA

KW - PTCL

UR - http://www.scopus.com/inward/record.url?scp=84961051803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961051803&partnerID=8YFLogxK

U2 - 10.3109/10428194.2016.1140760

DO - 10.3109/10428194.2016.1140760

M3 - Article

C2 - 26850659

AN - SCOPUS:84961051803

VL - 57

SP - 783

EP - 788

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -